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spective on clinical registries; to identify speciﬁc future
opportunities for registries to comprise an informatics
infrastructure for quality and efﬁciency measures that are
used for accountability; and to propose a model for a
future state characterized by an increasingly close inter-
relationship between registries and performance mea-
sure development. Speciﬁcally, this statement focuses on
how registries and performance measures are intertwined
and how registries will become even more crucial with
increasing focus on different types of measures, in-
cluding process measures, risk-adjusted outcome mea-
sures, and resource use measures, that can be used by
patients and purchasers. The writing committee antici-
pates that this statement will prove valuable to providers,
payers, patients, policy makers, and other interested
stakeholders.
1.1. Disclosures of Relationships With Industry
Every effort is made to avoid actual, potential, or
perceived conﬂicts of interest that may arise as a result of
relationships with industry or other entities. The work of
the Writing Committee was supported exclusively by the
American College of Cardiology (ACC) and the American
Heart Association (AHA), in collaboration with The Society
of Thoracic Surgeons (STS), without commercial support.
The Writing Committee members volunteered their time.
All members of the Writing Committee, as well as those
selected to serve as peer reviewers of this document, were
required to disclose all current relationships and those
existing within the 12 months before the initiation of the
project. It was also required that the Writing Committee
co-chairs and at least 50% of the Writing Committee have
no relevant relationships with industry or other entities.
Author and peer reviewer relationships with industry
and other entities relevant to the document are included
in Appendixes A and B. Additionally, to ensure complete
transparency, the writing committee members’ compre-
hensive disclosure information, including RWI not rele-
vant to the present document, is available as an online
supplement.
1.2. Clinical Registries and Quality Measurement in
Cardiovascular Disease
Among the substantial changes in delivery of medicine
over the past decades, 2 parallel developments are
particularly noticeable: 1) an increasing emphasis on
measuring and improving the quality and efﬁciency of
medical care; and 2) the proliferation of clinical registries
designed to understand care and outcomes in “real-
world” medical settings. Although there is general
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of care, it is important to note that submitting data to
registries is associated with a real cost to medical centers
and practices. In some cases, data collection for registries
duplicates reporting requirements for state and national
initiatives, requiring institutional “champions” of regis-
tries to advocate for securing additional funding to
support registry efforts.
Recently, registry operations and the development
of quality measures for the purpose of accountability
(referred to as “performance measures” according to the
ACC/AHA Task Force on Performance Measures) have
converged substantially. The development of quality
metrics in cardiovascular disease has accelerated signiﬁ-
cantly since the early 1990s, when the Cooperative Car-
diovascular Project, a national effort led by the Health
Care Financing Administration (now the Centers for
Medicare and Medicaid Services [CMS]), was initiated to
measure the quality of care for Medicare beneﬁciaries
with acute myocardial infarction (1). Since that time,
other payers, governmental agencies, and professional
organizations have become involved, greatly expanding
the reach of quality performance measurement for
cardiovascular disease.
The landscape of cardiovascular quality measurement
has become increasingly complex because of several
simultaneous developments. Legislative mandates are
realigning payment incentives away from fee-for-service
structures to reimbursement for the delivery of quality
care (2). The requirements for the endorsement of per-
formance measures by the National Quality Forum
(NQF)—an organization that develops and applies mea-
surement standards—have expanded (3). Payers and
healthcare consumers demand more meaningful and
comprehensive measures to characterize outcomes, qua-
lity, safety, efﬁciency of care, and the patient experience.
Additionally, the rapid deployment of electronic health
records (EHRs) has been accompanied by increasing in-
terest in quality measures that can be extracted from data
collected during routine care. The conﬂuence of these
factors has expanded both the promise and the challenge
of performance measurement.
Cardiovascular registries, which have a track record
of supporting clinical quality improvement (4–11), are
recognized as a potential solution to many of these
emerging challenges. For example, the American Tax-
payer Relief Act of 2012 (12) gave providers the option
of satisfying the requirements of the Physician Quality
Reporting System (PQRS) (13) by participating in quali-
fying registries. This legislation also required an exami-
nation by the Government Accountability Ofﬁce of
potential expanding roles for clinical registries. The
resulting report recommended that the U.S. Department
of Health and Human Services require, as a condition ofqualiﬁcation, that registries demonstrate improvements
in quality and efﬁciency (14). In 2013, the CMS introduced
the concept of qualiﬁed clinical data registries (15) into
the PQRS program. The PQRS program established strin-
gent requirements for registry designation but also made
it possible for qualiﬁed registries to develop their own
performance metrics on the basis of clinically enriched
data. In addition, the CMS has partnered with national
cardiovascular registries to develop robust measures of
patient outcomes (16). These various efforts represent
an evolution in the nexus of clinical registry data and
performance measurement.
2. INTRODUCTION
2.1. What Is a Clinical Registry?
A clinical registry is an observational database focused on
a clinical condition, procedure, therapy, or population.
Data are collected systematically for speciﬁed scientiﬁc,
clinical, or policy purposes. There are no mandated
approaches to therapy in clinical registries (as opposed to
registries associated with randomized controlled trials),
and clinical registries have relatively broad inclusion
criteria and few exclusion criteria (17,18). The National
Committee on Vital and Health Statistics deﬁnes a registry
as “an organized system for the collection, storage,
retrieval, analysis, and dissemination of information on
individual persons who have either a particular disease, a
condition (e.g., a risk factor) that predisposes [them]
to the occurrence of a health-related event, or prior
exposure to substances (or circumstances) known or
suspected to cause adverse health effects” (19). The focus
of clinical registries is on capturing data that reﬂect “real-
world” clinical practice in large, representative patient
populations. Well-designed and well-executed clinical
registries provide insights into patient characteristics,
comorbid conditions, patterns of care, quality of care,
safety, clinical outcomes, and comparative effectiveness
(17–19). Clinical registries play an increasingly impor-
tant role in gauging appropriate healthcare delivery,
including:
 Measuring appropriateness of care and disparities in
the delivery of care;
 Serving as public health surveillance systems;
 Supporting and measuring the effectiveness of quality
improvement;
 Evaluating factors that inﬂuence prognosis and quality
of life;
 Assessing healthcare effectiveness and safety; and
 Improving clinical outcomes, patient care experience,
and patient-reported outcomes for a variety of
conditions, including many cardiovascular diseases
(17,18,20–23).
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mation for patients’ decision making about their care and
can facilitate more effective payment and incentive
strategies.
Clinical registries can be classiﬁed on the basis of
the deﬁning characteristics of the patient population
enrolled—for example, patients who have had a proce-
dure, therapy, or encounter; patients with a particular
disease; and patients in a demographic group, including
but not limited to race, age, and sex (17). Registries can
also be categorized by function, such as whether the
registry is used for quality measurement, to provide
feedback to clinicians for quality improvement, for clin-
ical research, or to fulﬁll multiple functions. Clinical
registries can be either prospective or retrospective in
design and are developed and operated by many types
of entities, including professional societies, researchers,
research consortia, nonproﬁt organizations, government
agencies (e.g., the National Institutes of Health), and
industry (17,18).
Clinical registries have well-deﬁned purposes, and data
are systematically collected in a way designed to meet
these purposes (17,18). Clinical registries capture data
elements with standardized, granular, and consistent
data deﬁnitions and data standards (18,24). Historically,
data have been entered into clinical registries via medical
record abstraction and case report forms, although some
registries, such as the National Cardiovascular Data Reg-
istry’s (NCDR’s) ambulatory registry (PINNACLE) (25) and
TGA (The Guideline Advantage) (26,27) (AHA/American
Stroke Association’s collaboration with the American
Cancer Society and the American Diabetes Association
through the Preventive Health Partnership), extract
electronic data directly from the EHR.
Clinical registries are generally observational rather
than interventional, in that the care provided and recor-
ded in the registry is determined by clinical evidence and
judgment rather than dictated by a study protocol. Clin-
ical registries usually do not contain claims, administra-
tive data, resource utilization, or pharmacy records, but
they may integrate data from or be linked to such data
sources (17–19). Registries may also be dynamic; some are
designed to modify the behavior of participants by
providing timely feedback about process and outcomes of
care to foster active quality improvement intervention.
2.2. The Role of Clinical Registries
Clinical registries represent a foundational tool in the
cycle of developing evidence for best medical practices,
measuring the outcomes of these care processes, pro-
viding actionable feedback to clinicians, and improving
quality of care and outcomes. These activities span the
domains of patient care, research, and teaching, as well as
quality improvement and research, with the boundariesbetween these domains sometimes presenting ethical
and regulatory challenges (28).
Clinical registries can be used as a platform for devel-
oping evidence for best medical practices and performing
comparative-effectiveness research. The National In-
stitutes of Health–funded ASCERT (ACC–STS collaboration
on the Comparative Effectiveness of Revascularization
sTrategies) trial and the Agency for Healthcare Research
and Quality–funded COMPARE-HF (Compare the Effects
of Coreg CR and Coreg IR on HF in Subjects with Stable
Chronic HF) trial exemplify this approach (29,30). Ran-
domized trials are considered the criterion standard for
comparative effectiveness but historically have been
extremely expensive and have recruited restricted patient
populations, sometimes resulting in problematic general-
izability. Recent efforts have examined the possibility
of using clinical registries as a platform for conducting
pragmatic clinical trials (31,32), potentially accomplishing
the dual objectives of decreasing trial costs while simul-
taneously increasing the generalizability of the results.
Clinical registries are optimal tools for measuring
the outcomes of care processes, although special effort
may be necessary to ascertain nonfatal outcomes. Prop-
erly measuring clinical outcomes requires standardized
clinical nomenclature, uniform standards for deﬁning
and collecting data elements, strategies to adjust for the
complexity of patients, techniques to verify the com-
pleteness and accuracy of data, and longitudinal data
collection (21,33–36). All of these features would exist
in an ideal clinical registry, which would also have the
potential for collaboration across medical and surgical
subspecialties and across settings of care, as a means of
tracking outcomes.
Clinical registries can provide practitioners with accu-
rate and timely feedback about their own outcomes,
which are benchmarked against regional, national, or
even international aggregate data (21,37–44); however,
the ultimate goal is not measurement, but rather
improved quality of care and outcomes. Clinical registries
have been used to create standardized measures of
quality that have been endorsed by multiple professional
medical societies and the NQF. Compliance with registry-
based measures and the public reporting of these mea-
sures may lead to improvements in the overall quality of
care delivered (21,45–49).
2.3. Registries and Electronic Health Records
The penetration of clinical practice by EHRs has increased
rapidly since the introduction of the federal EHR ﬁnancial
incentive program in the Health Information Technology
for Economic and Clinical Health Act of 2009 (50,51).
Concomitant with payment incentives, the federal Ofﬁce
of the National Coordinator created mandatory “mean-
ingful use criteria” that must be met by EHRs before they
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are managed by the CMS at the hospital and physician
level (52). Among several objectives, meaningful use
criteria are meant to ensure that EHRs capture data in
ways that allow the data to be analyzed, reported as
performance measures, and ultimately used to improve
care. A few large EHR vendors captured a substantial
proportion of the growing EHR market and are accumu-
lating data entered by many clinicians in numerous
hospitals (53). Additionally, several companies provide
analytic services to assist health systems and physicians
with their raw EHR data (54–56). These companies pro-
vide performance information by using internally gener-
ated measures and benchmark performance on the basis
of data from all of their clients. Finally, the CMS offers
physicians the ability to use “a qualiﬁed clinical data
registry” (15) as a reporting option for the PQRS program
(13). A qualiﬁed clinical data registry is a CMS-approved
entity that collects medical or clinical data for a subset
of measures and can report data on these measures to the
physician for PQRS reporting purposes.
Some believe that EHR data will ultimately replace
registries as the premier sources of clinical information in
real-world settings; however, there are key differences
between EHRs and registries that have important im-
plications for the roles that each can play in evidence
generation, public reporting, and quality improvement.
Governance. The governance structures of registries
vary according to their purpose and the entities that
operate them. Those operated by researchers are
usually governed by the founding investigators, whereas
industry-funded registries often remain under the control
of their sponsoring companies. Specialty society registries
are typically governed by the membership of a particular
society, although joint specialty sponsorship is an
increasingly important variant (e.g., the STS/ACC TVT
[Transcatheter Valve Therapy] Registry) (7). They may
also include registry “customers” and patient represen-
tatives (5,6,57).
Data Speciﬁcations and Entry. Data entry into dedicated
clinical registries is typically accomplished by trained
abstractors who abstract information from the clinical
record in accordance with speciﬁc deﬁnitions and enter it
into the registry via case report forms (5–7,10,57). The
result is that registries contain highly reliable and valid
information. However, data in EHRs are captured in the
process of patient care by physicians and other members
of the clinical team for purposes other than analysis and
reporting. These clinicians might not use explicit, stan-
dardized deﬁnitions when documenting patient care.
This lack of standardization makes it more difﬁcult to:
1) allow for comparison and data aggregation of EHR data
among providers; and 2) use data from EHRs for national
and international comparisons and for accountabilitypurposes. Some of the data, such as diagnosis and treat-
ment codes, are collected and used primarily for billing
and insurance purposes. Although efforts have been
undertaken to establish common data models for EHR
data, these models are not yet in widespread use (58,59).
Data Quality. Registries generally have processes in
place to ensure data quality. For example, processes such
as those implemented by the STS National Database (6),
the GWTG (Get With The Guidelines) Registry (60), and
the NCDR (61) include ongoing training of abstractors and
data audit. The STS National Database contracts with an
external organization to conduct random audits of 10% of
its participant sites annually (34). In 2013, nearly 100,000
individual data elements were audited, with an excep-
tional overall accuracy rate of 96.6%. In contrast, EHR
data are generally not subject to formal audit. The quality
of EHR data is usually addressed through post hoc “data
scrubbing” and evaluation, through which data that
are likely erroneous are removed from further analysis.
Registries should continue to make concerted efforts to
improve data quality so as to strengthen the validity of
the data collected.
2.4. The Continuing Utility of Clinical Registries
in an Era of Electronic Health Records
Despite the growth of EHRs and EHR-derived databases,
clinical registries will continue to play an increasingly
important role in measuring healthcare outcomes, appro-
priateness of care, and disparities in the delivery of care,
and will serve as the basis for clinical and comparative-
effectiveness research. EHR data have important limita-
tions with regard to key cardiovascular data elements. For
example, contraindications to therapy and other critical
data elements might not be captured in discrete and hence
analyzable ﬁelds. Studies suggest that caution should be
exercised in using EHRs for quality monitoring (62), and
some studies suggest that the use of EHRs per se has not
resulted in better quality of care or outcomes (63–65). In
contrast, clinical registries have well-documented efﬁcacy
as instruments for surveillance; supporting andmeasuring
effectiveness of quality improvement; evaluating factors
that inﬂuence prognosis and quality of life; assessing
healthcare effectiveness and safety; and improving clinical
outcomes for heart disease, stroke, and other diseases
(17,18,20–23). Thus, clinical registries remain essential
and well-validated methods for measuring and improving
performance.
The future will likely involve some degree of integra-
tion of EHR and administrative data sources with registry
data. Many registries track patients for only a short period
of time after an initial event, although registries are
increasingly trying to follow patients for longer periods of
time (66), as is the case with the REACH (REduction of
Atherothrombosis for Continued Health) registry (67–69),
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data could facilitate longitudinal patient follow-up and
documentation of nonclinical outcomes, such as resource
use. Registries, in turn, could bring the discipline of
common data models and of systematic, structured
data deﬁnitions and data quality to EHR-derived data.
This would enable valid performance comparisons among
providers, as well as the creation of large, patient-
centered datasets that track individuals across diseases
and procedures and over time. In the future, registries
could also be used as platforms for multicenter, ran-
domized clinical trials (31,32). Registries hold the poten-
tial to become data network hubs linking clinical, claims,
and EHR data and could also link to patient-generated
data (e.g., symptoms, health status, and other patient-
reported data). This will enhance capabilities in the
conduct of comparative-effectiveness research, safety
surveillance, and clinical quality improvement, as well as
in providing meaningful feedback to clinicians on their
performance.
3. UNREALIZED OPPORTUNITIES TO
LEVERAGE CLINICAL REGISTRIES FOR
PERFORMANCE MEASUREMENT
3.1. Limited Intersections of Clinical Registries and
Performance Measure Development
Among professional societies and organizations that have
developed clinical registries, there is wide variation in the
degree to which these registries are integrated with the
organizations’ corresponding performance measurement
initiatives. Registry operations and performance mea-
surement are increasingly complex, technically sophisti-
cated activities that require specialized skills, and the
synergy between them may not always be appreciated
by external stakeholders.
Registries collect protected health information and
thus must adhere to privacy and informed-consent regu-
lations. Registry stewards must also engage in contractual
relationships with database participants, data warehouses
and analytical centers, vendors, and third parties, with
whom data may be shared under speciﬁc circumstances.
Registry operations are supervised by paid staff and
volunteers who oversee a complex array of database
functions, including data element speciﬁcations, data
security, privacy, data harvests, data quality checks and
audit, feedback reports to participants, and data manager
support.
Performance measurement is also technical and re-
quires a combination of clinical and statistical knowledge
about matters such as risk adjustment (33,38–40,71–78).
Even after measures are developed, they must be pilot-
tested and then, ideally, submitted to organizations
such as the NQF for endorsement. The submissionprocess requires demonstration of importance, evidence
base, scientiﬁc acceptability, usability, and feasibility,
all of which entail speciﬁc technical knowledge and so-
phisticated analytics (79). Ultimately, measures may be
reported publicly in a scientiﬁcally credible yet consumer-
friendly format, with such “report cards” potentially
having signiﬁcant implications for reputation, referrals,
and reimbursement.
If one accepts that clinical registries are a highly reli-
able clinical data source, the close interaction between
registry and performance activities is obvious. As the
requirements for endorsement of quality measures for
the purposes of public reporting have changed, the re-
lationships between registries and performance mea-
surement activities within professional organizations
have also evolved. For example, in the past, performance
measures developed by the ACC and AHA emanated from
the ACC/AHA Task Force on Performance Measures. Per-
formance measurement was viewed as distinct from
registry operations and had its own full-time and volun-
teer staff. Typically, the topics chosen for performance
measurement reﬂected cardiovascular conditions and
procedures with perceived gaps in care, as well as the
clinical interests of constituencies within the organiza-
tion. ACC/AHA task force work groups were challenged in
assessing issues of measure implementation. Measure
implementation has been assisted by registries, including
the PINNACLE Registry and TGA, both of which were
developed as means of putting ambulatory performance
measures into practice.
As the requirements for measurement endorsement
have grown to include measures that not only have strong
evidence but also have been tested for validity and
feasibility of implementation, this model of exclusively
work group–driven measurement development has be-
come less practical. For example, GWTG and some NCDR
registries have developed comprehensive sets of quality
metrics, yet the development, validation, and oversight of
those measures have been conducted largely indepen-
dently of the ACC/AHA Task Force on Performance Mea-
sures. Increasingly, measures have begun to emanate
directly from the registries because implementation and
validation are integral to registry operations. As the
model for measure development within the professional
organizations evolves, it will be important to ensure that
the process includes the appropriate methodological
support to guarantee the validity and reliability of
measures.
At the other end of the spectrum, organizations such
as the STS have historically included the “downstream”
by-products of clinical registry data (e.g., performance
measurement, public reporting, quality improvement)
as part of their database portfolio. Indeed, perfor-
mance measurement is the focus of the STS Quality
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Database structure. Some Quality Measurement Task
Force members have methodological expertise in pro-
vider proﬁling (e.g., statisticians with a special interest in
provider proﬁling). Other surgeon members serve in a
variety of database activities and have helped to design
database elements that are used to construct performance
measures. Involvement of statisticians, other proﬁling
experts, and clinical surgeons, as well as highly compe-
tent staff, ensures that measures derived from registries
are scientiﬁcally sound and clinically valid. Measures are
thereby well designed to both meet the requirements of
organizations such as the NQF and be acceptable to the
surgeons being measured. In fact, all end users should
be involved in the design and development process,
especially consumers and payers, with their input incor-
porated from the beginning.
3.2. Challenges and Barriers to Better Integration of Registries
and Performance Measure Development
To develop optimal performance measures on the basis of
clinical registry data, professional societies and other or-
ganizations will ﬁrst have to overcome the barriers to
implementing and maintaining their own clinical data
registries. As evidenced by substantial gaps in the disci-
plines covered by healthcare registries, there are signiﬁ-
cant barriers to starting a new registry. These include the
need for dedicated full-time staff, software vendors, data
warehouses, and analytical centers. In addition, registries
must generally rely on a cadre of committed volunteer
physician leaders who develop and periodically revise
data elements and oversee registry operations. In the
early stages of registry implementation, when participa-
tion levels are lower, ﬁxed costs may exceed revenues,
and societies must be willing to view these early losses as
an investment in the future. Government or commercial
support for both nascent and established registries would
be invaluable. As participation levels grow, clinical reg-
istries can become self-sustaining.
Other practical issues are also a challenge to more
widespread implementation of registries and their use in
developing performance measures. For example, with the
exception of a few areas, such as cardiovascular medicine
and surgery, little effort has beenmade to standardize data
element deﬁnitions across registries. This lack of stan-
dardization can produce confusion, with postoperative
kidney failure potentially meaning 1 thing for a patient
having heart surgery and quite another for patients having
neurosurgery or orthopedic surgery. Additionally, lack of
standardization creates barriers to moving beyond the
narrow focus of procedure- or diagnosis-speciﬁc registries
to more broad-based, linked registries that embrace the
entire spectrum of care experienced by most patients.
Widely accepted data quality standards are also lacking,despite the fact that such standards are 1 of the most
important features of any registry. Any registry that does
not have regular external audit programs demonstrating
high accuracy, such as those used in the STS National
Database (29,34) and NCDR registries (61,70), should not
be the basis for performance measures.
Together, the time frame required for data collection
and the nature of the outcomes collected constitute
another barrier to more effective use of registries.
Currently, most clinical registries collect clinical data
during the period of hospitalization or within 30 days
after discharge; however, stakeholders increasingly want
information on longer-term outcomes (e.g., survival, late
complications, readmissions, reinterventions, and func-
tional status), as well as nonclinical data, such as total
costs. These data are difﬁcult and prohibitively expensive
for registries to collect primarily, but they can often be
obtained by linking clinical registries to claims sources,
such as those available from the government (e.g.,
Medicare Provider Analysis and Review) and industry.
As noted previously, integration of EHR data into regis-
tries or ambulatory registries such as PINNACLE, which
extracts data from EHRs rather than requiring data
abstraction (70), would be alternative approaches to the
challenge of longitudinal patient tracking.
Finally, the growth of EHRs is both a challenge and an
opportunity with regard to the potential use of clinical
registries for performance measure development. The
largest single cost tohospitals for clinical registries is that of
data management personnel. Registry stewards consider
the expertise and dedication of these individuals to be
crucial aspects of registry operations, and they are a major
reason why registry data are more accurate and granular
than claims data; however, as hospitals increasingly use
EHRs, they understandably would prefer to automatically
extract some registry data elements directly from EHRs
rather than having to enter them manually. For some
data, such as laboratory results, dates of service, and de-
mographics, automatic extraction is feasible; however,
extraction from EHRs of many of the more detailed
elements in clinical registries will require the personnel
administering these 2 data sources to work collaboratively
on structured data element deﬁnitions or to blend elec-
tronic data abstraction with manual abstraction of non-
extractable concepts. Itwill beessential toensure that these
data elements are collected by EHRswith the same rigorous
attention to detail as displayed by clinical registries.
4. ENVISIONING THE FUTURE STATE
OF REGISTRIES
4.1. Why the Profession Should Deﬁne Quality Care
The explosion of clinical registries over the past decade
was catalyzed both by the need to test the feasibility of
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by a national focus on evidence-based medicine. Even
with the growth in the number of registries, there are still
broad clinical areas and speciﬁc procedures for which
registries do not currently exist but would be highly
beneﬁcial. Today, registries not only report a site’s per-
formance but can also quantify site variations in perfor-
mance. Because registries collect data from a broad
spectrum of providers, timely feedback reports provide a
means for hospitals and individual clinicians to evaluate
their performance against local, regional, or national
benchmarks for excellence, thus stimulating further
improvement.
More recent advances in linking registry data to Medi-
care and insurance claims have transformed registries
into dynamic entities with the ability to not only assess
but also inform the development of new performance
measures (80,81). Patients, clinicians, and stakeholders
are increasingly focused on clinical outcomes (and varia-
tions in outcomes across sites) as the key markers of
quality of care. The structure adopted by many contem-
porary registries (longitudinal vital status and read-
mission information; platform for feedback to clinicians,
sites, and physician champions) offers substantial ad-
vantages over other modalities of data collection and
positions them as entities that can both measure and
help deﬁne high-quality care.
4.2. Addressing the Current Challenges
Nonstandard terminology and ﬁnancial and knowledge
barriers have prevented many professional societies and
organizations from developing clinical registries and
many hospitals from implementing them. These chal-
lenges may seem overwhelming, but some have been
successfully addressed at local and regional levels and
within speciﬁc specialties. Broad dissemination of the
lessons learned from these successes, augmented by cre-
ative thinking, can lead to new and improved clinical
registries.
Standardization of data elements facilitates the linking
of registries within and across specialties. Although the
International Classiﬁcation of Diseases–9 and –10 codes
provide a common language, they often do not provide
the speciﬁcity and clinical granularity necessary for many
quality initiatives. Therefore, more detailed terminology
and deﬁnitions need to be developed. For example, the
International Pediatric and Congenital Cardiac Code pro-
vides a detailed, standard nomenclature for diagnoses
and procedures that is used by databases developed by
multiple societies and organizations serving the popula-
tion with congenital cardiac disease. These include the
European Society Association for Cardio-Thoracic Sur-
gery, Association for European Pediatric Cardiology, STS,
ACC, and Virtual Pediatric Intensive Care Unit (82).Similar common nomenclatures for other diseases will
support the development of new databases because these
nomenclatures can be imported rather than developed
de novo, and linking of databases will be facilitated by
providing common terms and deﬁnitions. In addition,
the adoption of such nomenclatures into administrative
databases, such as the inclusion of the International
Pediatric and Congenital Cardiac Code in International
Classiﬁcation of Diseases–11, will allow the strengths
of administrative data to be better used for quality
improvement. The collection of long-term patient data,
including both data on patient experience of care and
patient-reported outcomes, is complex and costly, yet is
increasingly important. The linking of clinical registries
to administrative databases is a valuable approach that
could be more useful if nomenclature were shared.
Linking registries to claims data and other longitudinal
data sources, such as EHRs, enables the creation of
datasets of patients with chronic diseases that can be
followed over many years, supporting the development
of population-based measures and measures of care
processes (83).
Cost is a barrier to the development and implementa-
tion of clinical registries. Although there is an initial cost
to societies and organizations, clinical registries can
become self-sustaining over time. All parties that beneﬁt
from analyses of registry data should provide the ﬁnancial
support required for registry development and ongoing
operations. This includes payers, who should provide
both direct and ﬁnancial support to registries and
to hospitals and clinicians who participate in recognized
registries, thus making participation economically
feasible. The reimbursement system should reward phy-
sician and hospital practices that improve patient care
and manage cost appropriately. Success stories need to be
shared to encourage those contemplating the develop-
ment of registries. Because hospitals may be reluctant
to implement new registries in a time of aggressive cost
containment, the role of registries in clinical care im-
provement and the subsequent ﬁnancial beneﬁt should be
emphasized. One example of such work is the Virginia
Cardiac Surgery Quality Initiative (84). This voluntary
consortium of 17 hospitals and 13 cardiac surgical prac-
tices in Virginia not only identiﬁed quality improvement
opportunities and tracked patient outcomes, but also
found opportunities for cost containment, such as
improved patient outcomes and decreased resource uti-
lization associated with the implementation of a blood
conservation guideline (85). From 2006 to 2011, cardiac
surgery practices that participated in the Virginia Cardiac
Surgery Quality Initiative and Anthem Blue Cross Blue
Shield received augmented payments and contracted
rates that were on the basis of adherence to clinical and
process metrics derived from performance measures from
FIGURE 1 The Role of Registries in the Cycle of Quality
Adapted from Califf et al. (92). QI ¼ quality improvement.
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ences in Michigan were funded by Blue Cross Blue Shield
of Michigan and more than paid for their investment
(86,87). The Michigan Society of Thoracic and Cardio-
vascular Surgeons Quality Collaborative is a voluntary
data and quality collaborative that uses the STS Adult
Cardiac Surgery Database (86). This pay-for-participation
model is funded partially by Blue Cross and Blue
Shield of Michigan. The opportunities provided for cost
containment, as well as ﬁnancial incentive programs
supported by payers, can help defray the cost of imple-
menting and maintaining clinical registries.
Clinical registries should interface with EHRs when
possible. Because data collection is time consuming and
costly, any opportunity to reduce effort and cost while
maintaining data quality should be pursued. The stan-
dardization of data elements will enable the linking of
registries with EHRs and allow for automated extraction
of some data elements from the patient’s record for the
purposes of longitudinal follow-up and performance
measure calculation. This will minimize manual data entry
requirements and adverse effects on clinical workﬂow.
The use of EHRs has resulted in an emphasis on
administrative and billing practices, through which EHR
data are often obtained. Less attention has been paid to
how clinical registries and quality initiatives can help
improve care for patients by tracking data across payers
and identifying areas for which care can be improved.
Both newly developing and more mature registries
should share with and learn from each other. The National
Quality Registry Network (NQRN) (88), formed by the
American Medical Association–convened Physician Con-
sortium for Performance Improvement, was established
for this purpose. The NQRN is a voluntary network of
private and public stakeholders that is intended to
develop and improve clinical registries for quality initia-
tives. The ACC and the STS participate in the NQRN,
which provides a venue for collaborative learning with
other specialty societies that have developed registries,
such as the American Academy of Orthopedic Surgeons
(89), the American Gastroenterological Association (90),
and the American Urological Association (91).
The NQRN is intended to facilitate knowledge sharing
between those who have mature registries and those
in the development phase. Because the NQRN is a
multi-stakeholder organization, end users of registries
will have considerable input. Because the NQRN brings
together registry stewards such as professional societies
and registry users (including hospitals, insurance com-
panies, and the federal government), issues such as
public reporting, potential business models, and mutually
beneﬁcial registry content can be discussed. Additionally,
patients, family caregivers, and consumers can also be
involved in this discussion. Through mentoring andproviding a forum to share templates, the NQRN plans
to assist emerging registries, develop data and quality
standards for all registries to ensure interoperability, help
design sustainable business models, identify areas where
registry data can be applied to quality initiatives, and
work toward the extraction of some registry data from
EHRs.4.3. Role of Clinical Registry Infrastructure/Registries
in Performance Measure Development
4.3.1. Identifying Gaps in Care and New Areas for
Performance Measure Development
Clinical registries are at the center of the cycle of quality
improvement, as depicted in Figure 1 (92).
Clinical registries can inform guidelines and per-
formance measure development by showing where
contemporary patterns of care are not consistent with
existing evidence-based recommendations. To have value
as a performance measure, a treatment should be evi-
dence based and linked to patient outcomes; additionally,
there should be gaps in current usage. Conversely, clinical
registries can also help demonstrate that it is time to
sunset an existing performance measure if utilization of
the treatment approaches 100%.
Additionally, registries can play important roles in
addressing gaps in care related to healthcare disparities.
The ACC and AHA have identiﬁed the evaluation of
healthcare disparities involving racial and ethnic minor-
ities, women, the elderly, individuals with multiple
comorbidities, and individuals with congenital heart
conditions as an important focus for applying registry
data (72). Registries have indeed proved useful in quan-
tifying differences in care and clinical outcomes in
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stakeholders with the necessary data infrastructure for
using performance measures in evaluating efforts to
correct identiﬁed disparities (93–99).
Beyond establishing the community need for a perfor-
mance measure, clinical registries can assist in the tech-
nical development and optimization of a performance
measure (71). Registries can demonstrate how various
deﬁnitions for numerators and denominators, as well as
exclusions, affect the performance measure. They can
also help in evaluating whether the measure can be
collected consistently across various sites and settings.
Validation of a measure’s reproducibility is necessary
before a performance measure can be recommended for
benchmarking provider performance. Additionally, clin-
ical registries can help in evaluating how feasible it is for
providers to collect a performance measure in routine
clinical practice. Such feasibility testing includes assess-
ing whether the measure can be collected routinely and
with reasonable effort and cost. In fact, the NQF now
requires evaluation of measure reproducibility, validity,
and feasibility within a clinical registry or across multiple
sites before a measure may be considered for their
national performance measure recommendation. Inclu-
sion of a performance measure within a clinical registry
therefore provides not only an excellent means of devel-
oping and evaluating a new performance measure, but
also an ongoing mechanism for continued reﬁnement. Of
vital importance, clinical registries can be used to eval-
uate the process–outcome link for process-based perfor-
mance measures. When no such association is found,
those measures of processes that do not directly improve
outcomes can be considered for retirement or can be
revised (100,101). Registry data have also been used to
develop and validate robust risk-adjustment models to
report outcomes measures that account for case mix
(29,38–40,102–104).
4.3.2. Informing the Development of the Next Generation of
Performance Measures: More Focused on Outcomes and
Symptom Management and Based on Real-World Data
Increasingly, public and governmental agencies are
requesting that performance measures focus more on
patient clinical outcomes and patient-reported symp-
toms, physical function, and quality of life (71,72,105).
Current registries typically collect information on pa-
tients’ symptoms, but these assessments are often not
collected directly from the patient, nor do they use stan-
dardized instruments or methods. Clinical registries must
adapt to collect patient-centric performance measures.
The development of novel electronic tools for collecting
standardized, patient-reported outcomes will assist this
process. Capturing patient-generated data may also
facilitate better communication between patients andclinicians and greater patient/family engagement in the
care process.
Clinical registries typically collect clinical outcomes
(complications, death) in a cross-sectional manner (e.g.,
in hospital or over a period of 30 days), but there is
growing value in understanding longer-term patient
outcomes. Collection of longitudinal outcomes by clinical
registries has been facilitated by linking these traditional
databases with claims information (28,29,80,81) and other
outpatient clinical registries.
To be interpreted meaningfully, outcome-based per-
formance measures should be adjusted for potential
differences in the types of patients treated by various
providers. Speciﬁcally, it is important to determine the
degree to which any differences in outcomes seen among
providers are due to true differences in care quality
rather than differences in patient characteristics. Clinical
registries can be a means of accurately collecting data
on patient demographics, socioeconomic status, disease
severity, and concomitant comorbid illness. Adjustment
for socioeconomic status is now being studied by the
NQF for certain measures, such as readmission, that are
affected by factors that are not entirely within the control
of the hospital and could affect outcomes (106). Addi-
tionally, the data contained in large registries provide
an adequate sample size for developing and validating
the statistical models required for risk adjustment of
performance measures.
4.3.3. Publicly Reporting Measure Results
For the ﬁrst 30 years of their existence, most society-
based clinical registries were used to generate conﬁden-
tial feedback for providers; however, in 2002, the CMS
implemented the “Hospital Compare” web site, which
provided the public with hospital-level process and out-
come performance measure data for multiple common
conditions (107). This, along with some state and payer
initiatives, ushered in the era of public provider report-
ing. In 2010, the STS began to voluntarily publish coro-
nary artery bypass graft procedure performance measure
data in Consumer Reports and on the STS web site (108).
Within the ﬁrst 3 years of the initiation of the program,
nearly one-half of STS participant hospitals had agreed to
share their data publicly via this mechanism (109). Simi-
larly, the ACC has published a health policy statement
deﬁning 6 core principles of public reporting and has
initiated a pilot program for voluntary, hospital-level
public reporting (105).
4.4. Continuing Role for Performance Measure Developers
Developers of performance measures will continue to play
an important role in creating methodology, identifying
writing committees, and obtaining peer review and
endorsement for their measures. Criteria for acceptable
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ACC and the AHA (71,72,110–113), describe how candidate
measures are selected, developed, and used (e.g., for
public reporting or internal quality improvement). Only
those guideline recommendations that are valid, action-
able, measurable, and of acceptable value (e.g., cost-
effective care), should be considered as the basis for
public reporting and pay-for-performance measures. If
developers believe a measure does not meet all of these
criteria, they will recommend that it be used for quality
improvement only (112), at least initially.
Developers may continue to submit their measures to
an endorsing body such as the NQF. Endorsement often
requires that developers provide evidence that a gap in
care exists, that the data for the measure can be obtained,
and that the measure can be reported back to providers.
Developers may also seek to have measures adopted by
federal, state, or private payers without having these
measures endorsed by an entity such as the NQF. For
example, numerous measures used in the Qualiﬁed Clin-
ical Data Registry for PQRS reporting are not currently
endorsed by the NQF but were determined by the CMS to
be important for determining physician performance.
Ultimately, developers of performance measures will rely
on registries to provide these data on the existence
of gaps in care and evidence that the performance mea-
sure can be calculated and presented to the relevant
stakeholders.
Once developed, a performance measure will need to
be maintained by developers through periodic reviews of
published data and guidelines to ensure that the mea-
sure remains relevant to clinical practice. Developers will
need to demonstrate to clinicians and administrators:
1) that the measure has value; and 2) that the measure
has led to an improvement in care and patient outcomes.
A measure developer may solicit public comment
and, through this mechanism, try to secure feedback
from patients, consumer organizations, and payers on
new or revised versions of measures. Registries will
play an important role in documenting any change in
practice or outcome after the implementation of a new
measure.
Developers of performance measures will also be
expected to promote their measures to health systems
(e.g., hospital networks) and payers (e.g., CMS). Measure
developers may also seek to work with consumer orga-
nizations on how best to educate consumers about why
the measures are important to consumers. Fortunately,
such measure-promotion efforts will be synergistic with
registry-promotion activities. Through advocacy for wider
measure adoption, developers can simultaneously pro-
mote use of their performance measures and the registries
that report those measures, thereby furthering the goals
of patient-centered care.5. SUMMARY
The futures of registries and performance measurement
are intertwined. The worldwide role of registries as tools to
capture and analyze data will increase, and the parallel
demand for performance measures will result in prefer-
ential use of these data because they are more credible and
widely accepted than other sources and can be more fully
risk adjusted. The nexus of clinical registries and per-
formance measures will become even more important as
risk-adjusted outcomes data are used for high-stakes ap-
plications, such as public report cards, preferred provider
networks, and reimbursement. When feasible, limitations
of clinical registries, such as their data collection burden,
must be mitigated by automatic extraction of some data
elements from EHRs. This will be possible only for those
variables for which the integrity of clinical registry content
will not be compromised by automatic EHR data extrac-
tion. Similarly, the value of clinical registries, the data of
which historically have been limited to short-term out-
comes, will be enhanced through linkages with other data
sources, such as claims data. Sources such as claims data
can provide information on long-term outcomes, resource
use, rehospitalizations, and reinterventions. These link-
ages will require methods for identifying patients across
data sources. Also needed is clariﬁcation by the federal
government of Common Rule and Health Insurance
Portability and Accountability Act regulations, because
lack of clarity in these rules sometimes dissuades pro-
viders from submitting data.
By measuring and reporting registry performance to
clinicians, individual sites, and integrated healthcare net-
works, as well as publicly reporting when appropriate,
registries will be able to inﬂuence care profoundly. This will
include iterative changes occurring as a result of routine,
nationally benchmarked feedback reports, as well as ran-
domized clinical trials embedded into ongoing registries,
such as the TASTE (Thrombus Aspiration in ST-Elevation
myocardial infarction) trial, which was performed in the
Swedish Coronary Angiography and Angioplasty Registry
(31,32), and the SAFE PCI for Women (Study of Access Site
for Enhancement of PCI for Women) study, which used the
NCDR’s CathPCI Registry (114). Measuring and reporting
registry performance data would facilitate the empirical
determination of speciﬁc process-improvement strategies
that result in improved patient-centered outcomes. As
clinical registries cover progressively more of the health-
care landscape and are supplemented by additional data
from EHRs, claims databases, and other data sources
(e.g., industry databases, patient-reported information
from personal health records and websites [“big data”]), we
will beneﬁt from insights into real-world practice that have
not yet been possible, ultimately improving healthcare
delivery and patient outcomes.
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